Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Nov 2019
Historique:
received: 08 05 2019
revised: 22 07 2019
accepted: 04 08 2019
pubmed: 20 8 2019
medline: 22 11 2019
entrez: 18 8 2019
Statut: ppublish

Résumé

Intrinsically disordered proteins are an emerging class of proteins without a folded structure and currently disorder-based drug targeting remains a challenge. p53 is the principal regulator of cell division and growth whereas MDM2 consists its main negative regulator. The MDM2-p53 recognition is a dynamic and multistage process that amongst other, employs the dissociation of a transient α-helical N-terminal ''lid'' segment of MDM2 from the proximity of the p53-complementary interface. Several small molecule inhibitors have been reported to inhibit the formation of the p53-MDM2 complex with the vast majority mimicking the p53 residues Phe19, Trp23 and Leu26. Recently, we have described the transit from the 3-point to 4-point pharmacophore model stabilizing this intrinsically disordered N-terminus by increasing the binding affinity by a factor of 3. Therefore, we performed a thorough SAR analysis, including chiral separation of key compound which was evaluated by FP and 2D NMR. Finally, p53-specific anti-cancer activity towards p53-wild-type cancer cells was observed for several representative compounds.

Identifiants

pubmed: 31421630
pii: S0223-5234(19)30722-6
doi: 10.1016/j.ejmech.2019.111588
pmc: PMC7008132
mid: NIHMS1066795
pii:
doi:

Substances chimiques

6-chloroindole 0
Antineoplastic Agents 0
Benzylamines 0
Cyanides 0
Formates 0
Indoles 0
Intrinsically Disordered Proteins 0
Tumor Suppressor Protein p53 0
formic acid 0YIW783RG1
MDM2 protein, human EC 2.3.2.27
Proto-Oncogene Proteins c-mdm2 EC 2.3.2.27

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111588

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM097082
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Références

J Biol Chem. 2000 Sep 22;275(38):29426-32
pubmed: 10884388
J Health Econ. 2016 May;47:20-33
pubmed: 26928437
J Am Chem Soc. 2008 May 21;130(20):6472-8
pubmed: 18435534
PLoS One. 2012;7(3):e32839
pubmed: 22427896
PLoS One. 2014 Feb 14;9(2):e87133
pubmed: 24551051
Nat Struct Biol. 2001 Nov;8(11):923-5
pubmed: 11685234
Cell Cycle. 2010 Mar 15;9(6):1104-11
pubmed: 20237429
Mol Cell Biol. 1993 Jul;13(7):4107-14
pubmed: 7686617
J Am Chem Soc. 2012 Oct 17;134(41):17059-67
pubmed: 22991965
Eur J Med Chem. 2017 Jan 27;126:384-407
pubmed: 27907876
Nature. 2000 Nov 16;408(6810):307-10
pubmed: 11099028
J Mol Biol. 2005 Jul 15;350(3):587-98
pubmed: 15953616
J Med Chem. 2007 Jul 26;50(15):3457-64
pubmed: 17602601
Cell Cycle. 2008 Aug;7(15):2441-3
pubmed: 18677113
Expert Opin Drug Discov. 2016;11(1):65-77
pubmed: 26549326
Structure. 2013 Dec 3;21(12):2095-7
pubmed: 24315455
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14801-6
pubmed: 10611293
J Med Chem. 2010 Jul 22;53(14):5061-84
pubmed: 20345171
Chem Rev. 2014 May 14;114(9):4749-63
pubmed: 24712885
Cell. 1997 Feb 7;88(3):323-31
pubmed: 9039259
Protein Sci. 2013 Jun;22(6):693-724
pubmed: 23553817
Science. 1996 Nov 8;274(5289):948-53
pubmed: 8875929
ChemMedChem. 2016 Apr 19;11(8):757-72
pubmed: 26676832
J Org Chem. 2009 Dec 18;74(24):9490-6
pubmed: 19928812
Prog Nucl Magn Reson Spectrosc. 2013 Aug;73:1-16
pubmed: 23962882
J Am Chem Soc. 2012 Apr 18;134(15):6855-64
pubmed: 22444248
Bioorg Med Chem Lett. 2015 Dec 15;25(24):5661-6
pubmed: 26584879
J Med Chem. 2006 Jun 15;49(12):3432-5
pubmed: 16759082
Org Lett. 2015 Apr 17;17(8):2002-5
pubmed: 25824100
Biochemistry. 2001 Jan 16;40(2):336-44
pubmed: 11148027
ACS Chem Biol. 2014 Mar 21;9(3):802-11
pubmed: 24405416
Expert Opin Ther Pat. 2019 Mar;29(3):151-170
pubmed: 30822185
Cell Cycle. 2007 Oct 1;6(19):2386-92
pubmed: 17938582
Science. 1996 Nov 29;274(5292):1531-4
pubmed: 8929414
BMC Bioinformatics. 2009 Dec 03;10 Suppl 15:S6
pubmed: 19958516
Cell Cycle. 2009 Apr 15;8(8):1176-84
pubmed: 19305137
Medchemcomm. 2017 May 1;8(5):1046-1052
pubmed: 29034069
Structure. 2013 Dec 3;21(12):2143-51
pubmed: 24207125
J Mol Biol. 2018 Aug 3;430(16):2321-2341
pubmed: 29655986
Angew Chem Int Ed Engl. 2010 Jul 19;49(31):5352-6
pubmed: 20575124
Nature. 1992 Jul 2;358(6381):15-6
pubmed: 1614522
Org Lett. 2003 Apr 3;5(7):1047-50
pubmed: 12659570
Bioorg Med Chem Lett. 2012 May 15;22(10):3498-502
pubmed: 22507962
Sci Rep. 2016 Mar 02;6:22298
pubmed: 26931396
Oncogene. 1994 Sep;9(9):2523-9
pubmed: 8058315
Cell Mol Life Sci. 1999 Jan;55(1):96-107
pubmed: 10065155
J Med Chem. 2013 Feb 28;56(4):1363-88
pubmed: 23145854
Br J Cancer. 2004 Oct 18;91(8):1415-9
pubmed: 15452548
Curr Opin Chem Biol. 2008 Jun;12(3):281-91
pubmed: 18501203
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1645-8
pubmed: 12552135
Trends Biochem Sci. 2012 Dec;37(12):509-16
pubmed: 22989858
J Biomol NMR. 1992 Nov;2(6):661-5
pubmed: 1490109
Cancer Res. 2016 Sep 15;76(18):5189-91
pubmed: 27635040
Biochim Biophys Acta. 2013 May;1834(5):932-51
pubmed: 23269364
Structure. 2015 Dec 1;23(12):2246-2255
pubmed: 26636255
ACS Med Chem Lett. 2017 Sep 20;8(10):1025-1030
pubmed: 29057045
J Magn Reson B. 1995 Jul;108(1):94-8
pubmed: 7627436
J Med Chem. 2017 May 25;60(10):4234-4244
pubmed: 28482147
FEBS J. 2019 Apr;286(7):1360-1374
pubmed: 30715803
ACS Comb Sci. 2015 Sep 14;17(9):493-9
pubmed: 26226194
Protein Sci. 2018 Jan;27(1):229-232
pubmed: 28921842

Auteurs

Constantinos G Neochoritis (CG)

Department of Pharmacy, Drug Design Group, University of Groningen, Antonius Deusinglaan 1, 9700 AD, Groningen, the Netherlands.

Jack Atmaj (J)

Department of Pharmacy, Drug Design Group, University of Groningen, Antonius Deusinglaan 1, 9700 AD, Groningen, the Netherlands; Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.

Aleksandra Twarda-Clapa (A)

Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.

Ewa Surmiak (E)

Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.

Lukasz Skalniak (L)

Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.

Lisa-Maria Köhler (LM)

Department of Internal Medicine III, Klinikum der Universität München, Munich, Germany; Clinical Co-Operation Group Immunotherapy at the Helmholtz Institute Munich, Munich, Germany.

Damian Muszak (D)

Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.

Katarzyna Kurpiewska (K)

Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.

Justyna Kalinowska-Tłuścik (J)

Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.

Barbara Beck (B)

Department of Internal Medicine III, Klinikum der Universität München, Munich, Germany; Clinical Co-Operation Group Immunotherapy at the Helmholtz Institute Munich, Munich, Germany.

Tad A Holak (TA)

Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.

Alexander Dömling (A)

Department of Pharmacy, Drug Design Group, University of Groningen, Antonius Deusinglaan 1, 9700 AD, Groningen, the Netherlands. Electronic address: a.s.s.domling@rug.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH